Gesetzliche Krankenversicherung GKV

  • Pressemitteilung
    01.03.2012

    In contrast to the Green Party, which is going to make a prevention law part of its agenda for „tomorrow‘s healthcare policy“ as well as an issue for its election campaign, the present CDU/FDP government is planning no such law, the Deputy Chairman of the CDU/CSU parliamentary group Johannes Singhammer said at the BVMed round of health talks „Gesprächskreis Gesundheit“. Mehr

  • Pressemitteilung
    28.03.2012

    Medtech companies will have to increasingly address the „benefit analysis“ topic in connection with new examination and treatment methods. The industry should develop a reimbursement scheme for innovations early on in the game, and pursue it strategically. The topic of „benefit analysis“ will at first be restricted to class IIb and III medical devices with higher risk, which make up barely 10 percent of all medical devices. This was the upshot of the „Innovation Access for Medical Technologies“ conference held in Cologne in March 2012. Mehr

  • Pressemitteilung
    29.11.2012

    The sales growth rate of medical technology companies in Germany has weakened compared to last year, dropping from 5.3 to 4.4 percent. Because of sustained downward pressure on prices, increased raw material prices and higher receivables, the profit situation has deteriorated. Nonetheless, the medtech industry has continued to create additional jobs in 2012. This is the summary of the Autumn Survey 2012 of the German Medical Technology Association (BVMed) for the world‘s largest medicine trade fair MEDICA in Düsseldorf, in which 101 member companies participated. Mehr

  • Pressemitteilung
    28.09.2013

    The growth in the case volumes of surgeries per se does not constitute a problem; instead, it reflects the effectiveness and quality of medical care in Germany. This is the opinion expressed by Prof. Dr. Frank Ulrich Montgomery, president of the German Medical Association (GMA) and Ralf Heyder, Secretary General of the Association of University Hospitals in Germany (Verband der Universitätsklinika Deutschlands, VUD) on the occasion of the BVMed discussion "Do we go for surgery too quickly in Germany – or is our patient care superior?". The discussion took place against the background of recent OECD figures according to which Germany is supposed to be surgery world champion. Mehr

  • Pressemitteilung
    30.10.2013

    The trial regulation for new examination and treatment methods of medical technologies can help accelerating the pace at which medtech innovations are accepted into comprehensive coverage. The trial regulation offers a simplified and quicker access to the outpatient sector, claimed Olaf Winkler of BVMed on the intention of German legislation at the conference ”The Trial Regulation for Medical Devices in Practice”. Dr. Fülöp Scheibler from the Institute for Quality and Economic Efficiency in Healthcare (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG) is optimistic about the trial regulation: ”It is an additional option. Mehr


©1999 - 2022 BVMed e.V., Berlin – Portal für Medizintechnik